Trial Profile
A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary Myelofibrosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2023
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary) ; Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms POMINC
- 09 May 2023 Planned End Date changed from 1 May 2024 to 1 Apr 2026.
- 09 May 2023 Planned primary completion date changed from 1 May 2022 to 1 Apr 2024.
- 17 Jun 2022 Clinical and genetic (n=91) results of ruxolitinib plus pomalidomide in myelofibrosis with anemia, presented at the 27th Congress of the European Haematology Association.